Denver—Many patients are abandoning or delaying initiation of their oral oncolytic therapies because of the high cost of the medication, according to the results of a survey of pharmacy staff and administrators presented at the 2018 annual meeting of the Hematology/Oncology Pharmacy Association (poster TR165).
More than one-third of survey respondents reported that they had patients who had abandoned therapy due to high cost. Most respondents reported that they had